Jan 11,2023

Welldoc Earns 2023 BIG Innovation Award

Welldoc®, a digital health leader revolutionizing chronic care, today announced that it has been named a winner in the 2023 BIG Innovation Awards presented by the Business Intelligence Group. The BIG Innovation Award has been granted to Welldoc for its chronic care platform that integrates personalized, real-time and actionable insights into the daily lives of individuals living with chronic conditions and comorbidities, enabling improved health and outcomes.

View Analyst & Ambassador Comments
Go to original news
Jan 12,2023

Insulet to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

Insulet Corporation today announced plans to release its financial results for the fourth quarter and full year of 2022 on February 23, 2023 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

View Analyst & Ambassador Comments
Go to original news
Jan 12,2023 TOP STORY

Diabeloop and EOFlow Partner to Offer a Wearable AID With a Smartphone App

EOFlow and Diabeloop announced that they have partnered to bring an AID system, connecting EOFlow’s wearable insulin pump EOPatch, a third-party continuous glucose monitoring (CGM) device and Diabeloop’s automated insulin delivery (AID) algorithm integrated in the Diabeloop’s smartphone app, currently in development.

COLLABORATION PARTNERSHIP

#connected device

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Jan 12,2023

Nearly Half of Medicare Advantage Beneficiaries Would Switch to a Different MA Plan If It Offered Diabetes Reversal, New Survey from Virta Health Reveals

A newly conducted survey from type 2 diabetes reversal leader Virta Health revealed that 47% of Medicare Advantage (MA) members with type 2 diabetes would switch to a different health plan if it offered diabetes reversal. Of the many potential benefits, the majority named less medication as the top perk of diabetes reversal. In Virta’s survey, over 90% of respondents reported taking at least one diabetes drug; nearly half were on insulin.

View Analyst & Ambassador Comments
Go to original news
Jan 13,2023

How Dexcom aims to extend its mission beyond diabetes

CEO Kevin Sayer explains how, following the launch of the next-generation Dexcom G7, the company is looking toward the future. Dexcom ended 2022 strong, receiving FDA clearance for its next-generation G7 continuous glucose monitor (CGM). With a U.S. launch imminent, the company could keep its efforts centered on the diabetes space. Instead, the company could keep its efforts centered on the diabetes space. Instead, the company plans to broaden its focus even wider.

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 16,2023

The Self Monitoring Blood Glucose Devices Market Is Set To Reach $20 Billion By 2027, Driven By Rising Diabetes Cases - By The Business Research Company

The global self-monitoring blood glucose (SMBG) devices market size grew from $13.24 billion in 2022 to $14.59 billion in 2023 at a compound annual growth rate (CAGR) of 10.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term.

#bgm

View Analyst & Ambassador Comments
Go to original news
Jan 17,2023 TOP STORY

Dexcom G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program

Dexcom, Inc. is pleased to announce that coverage for Dexcom G6 rtCGM System on the Non-Insured Health Benefits (NIHB) Program has been expanded to include all clients living with type 1 diabetes. This announcement expands upon coverage already in place for clients aged 2 to 19 on intensive insulin therapy, giving even more First Nations and Inuit people access to this standard of care, potentially helping them to have more control over a life-long chronic illness.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 17,2023

Your chance to comment on NICE's guidance on using hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.

The National Institute for Health and Care Excellence (NICE) is producing guidance on using Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes in the NHS in England. The diagnostics advisory committee has considered the evidence and the views of non-company consultees and commentators, clinical experts and patient experts and patients can now comment on the Appraisal Consultation Document (ACD).

#closed loop

View Analyst & Ambassador Comments
Go to original news
Jan 19,2023

Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement

Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2022 financial results on Thursday, Feb. 2, 2023. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time.

View Analyst & Ambassador Comments
Go to original news
Jan 19,2023

Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2022 results after the financial markets close on Wednesday, February 22, 2023. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2022 financial and operating results.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES